LncRNA SBF2 Antisense RNA 1 Accelerates the Progression of Colon Cancer via PI3K/Akt/mTOR Signaling Pathway by Targeting miR-506-3p/ZEB1 Axis

Colon cancer is a severe digestive system malignant tumor. It is particularly urgent to make a thorough inquiry into colon cancer. The role of lncRNA SBF2 Antisense RNA 1 (SBF2-AS1) in the progression of this disease was explored. RT-PCR was undertaken to detect lncRNA SBF2-AS1 expression, miR-506-3p, and ZEB1 in normal HIEC, HCT116, LoVo, SW480, and SW620 cells. Sh-SBF2-AS1, miR-506-3p mimic, ZEB1 inhibitor, and controls were transfected. Proliferation was verified by CCK-8 assay. Invasion and migration ability were monitored via wound healing and Transwell assay. The colon cancer model was established to research the role of lncRNA SBF2-AS1 in vivo. LncRNA SBF2-AS1 was with high level in colon cancer samples, and the survival rate was positively related to SBF2-AS1 level of patients. Down-expressed SBF2-AS1 decreased the development of colon cells. Furthermore, we predicted SBF2-AS1 targeted binding to miR-506-3p and proved that the downstream gene was ZEB1 by the bioinformatic and experimental means. In addition, we observed that the tumor-accelerate effects of SBF2-AS1 in colon cancer were mediated by PI3K/Akt/mTOR pathway. Finally, we referred that sh-SBF2-AS1 effectively inhibits the development of colon cancer in vivo. LncRNA SBF2-AS1 has involved the PI3K/Akt/mTOR signaling pathway of colon cancer via regulating the miR-506-3p/ZEB1 axis.